source
- Allogene announces CEO David Chang will step downAllogene Therapeutics disclosed that its chief executive, David Chang, will be leaving the company. The firm indicated that a succession plan is in place, though it did not provide a specific timel…
- Replimune to resubmit melanoma therapy RP1 to FDA after two prior rejectionsReplimune announced on Friday that it will again submit its advanced melanoma candidate, RP1, to the U.S. Food and Drug Administration for review. The company says the filing follows new discussion…